

Reference number
2057-A

SPECIALTY GUIDELINE MANAGEMENT

VIMIZIM (elosulfase alfa)

POLICY

I. INDICATIONS

The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.

FDA-Approved Indication

Vimizim is indicated for patients with Mucopolysaccharidosis type IVA (MPS IVA, Morquio A syndrome).

All other indications are considered experimental/investigational and not medically necessary.

II. DOCUMENTATION

Submission of the following information is necessary to initiate the prior authorization review:

- A. Initial requests: N-acetylgalactosamine-6-sulfatase enzyme assay or genetic testing results supporting diagnosis.
- B. Continuation requests: chart notes documenting a clinically positive response to therapy, which shall include improvement, stabilization, or slowing of disease progression.

III. CRITERIA FOR INITIAL APPROVAL

Mucopolysaccharidosis IVA (MPS IVA, Morquio A syndrome)

Authorization of 12 months may be granted for treatment of MPS IVA (Morquio A syndrome) when the diagnosis of MPS IVA was confirmed by enzyme assay demonstrating a deficiency of N-acetylgalactosamine-6-sulfatase enzyme activity or by genetic testing.

IV. CONTINUATION OF THERAPY

Authorization of 12 months may be granted for continued treatment in members requesting reauthorization for an indication listed in Section III who have a clinically positive response to therapy, which shall include improvement, stabilization, or slowing of disease progression.

V. REFERENCES

1. Vimizim [package insert]. Novato, CA: BioMarin Pharmaceutical Inc.; December 2019.
2. Hendriksz CJ, Berger KI, Giugliani R, et al. International guidelines for the management and treatment of Morquio A syndrome. *Am J Med Genet A*. 2015;167A(1):11-25.
3. Clinical Consult: CVS Caremark Clinical Programs Review. Focus on Enzyme Disorders. April 2021.